UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.
An expert analyst thinks 10x Genomics is fairly priced and raised their guess for what the stock *could* be worth from $20 to $68—a big jump! When experts change their price targets, it's worth noticing what might have changed at the company, like new products or better results.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.